L428 cells derived from Hodgkin's disease produce E rosette-inhibiting
factor
I Katay, U Wirnitzer, H Burrichter, C von Kalle, E Schell-Frederick, V Diehl and M Schaadt
Medizinische Klinik I, der Universitat zu Koln, West Germany.
Diminished rosetting capacity of T cells is a well-known phenomenon in
Hodgkin's disease, and inhibitors of E rosette formation have been reported
to be present in the plasma of patients with Hodgkin's disease. The cell
line L428, representing an in vitro counterpart of Hodgkin and
Sternberg-Reed cells, could be shown to release a factor capable of
suppressing the binding of sheep red blood cells (SRBC) to normal
peripheral-blood T lymphocytes or to a T-cell line (L735). At maximally
effective concentrations, RIF (rosette inhibiting factor) inhibited T
lymphocyte rosetting by approximately 40% (mean from 184 healthy controls).
The diminished E rosetting of T lymphocytes from Hodgkin's patients was not
further suppressed by added RIF. This factor inhibited binding of SRBC to
their target cells at 37 degrees C but not at 4 degrees C. The factor could
be stored lyophilized at -20 degrees C and was stable at 56 degrees C (30
minutes). RIF was inactive below pH 6 and above pH 9 or after trypsin
digestion. Purification by affinity, ion exchange, and molecular sieve
chromatography showed activity peaks at 12.5 Kd, 25 Kd, 50 Kd, and 100 Kd.
Volume 76,
Issue 4,
pp. 791-796,
08/15/1990
Copyright © 1990 by The American Society of Hematology
